<DOC>
	<DOC>NCT02939872</DOC>
	<brief_summary>The purpose of this study is to evaluate optimal duration of antiplatelet therapy after Bioresorbable Vascular Scaffold implantation to reduce late coronary arterial thrombotic events.</brief_summary>
	<brief_title>Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events</brief_title>
	<detailed_description />
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Ticlopidine</mesh_term>
	<mesh_term>Clopidogrel</mesh_term>
	<criteria>Age 19 and more On dual antiplatelet therapy and between 12months and 14months from Bioresorbable Vascular Scaffold implantation No history of death, serious myocardial infarction, stroke, repeat revascularization, or major bleeding Contraindication to antiplatelet therapy Need to continue clopidogrel due to stroke, peripheral disease, significant carotid disease or recent acute coronary syndrome Major bleeding history or bleeding diathesis Pregnancy</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>DAPT</keyword>
	<keyword>BVS</keyword>
	<keyword>Bioresorbable Vascular Scaffold</keyword>
	<keyword>Dual Antiplatelet Therapy</keyword>
</DOC>